StockData
Neumora Therapeutics, Inc. logo

Neumora Therapeutics, Inc. (NMRA) stock

NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$0.37+0.03 (+9.66%)

Close on Nov 18, 2026Market cap $68.92MP/E –Yield –

Neumora Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Neumora Therapeutics's free cash flow for the twelve months ending Dec 31, 2023 was -$163.40M. For fiscal 2023 it was -$163.40M.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$163.40M–
FY2022Dec 31, 2022-$115.41M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$51.49M–
Q3 FY2023Sep 30, 2023-$47.81M–
Q2 FY2023Jun 30, 2023-$31.02M–
Q1 FY2023Mar 31, 2023-$33.08M–
Q4 FY2022Dec 31, 2022-$30.39M–

More Neumora Therapeutics figures

See a number that looks wrong?